DOCSLIB.ORG

L1 (CD171) Is Highly Expressed in Gastrointestinal Stromal Tumors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
L1 (CD171) Is Highly Expressed in Gastrointestinal Stromal Tumors Modern Pathology (2006) 19, 399–406 & 2006 USCAP, Inc All rights reserved 0893-3952/06 $30.00 www.modernpathology.org L1 (CD171) is highly expressed in gastrointestinal stromal tumors Jussuf T Kaifi1, Andrea Strelow1, Paulus G Schurr1, Uta Reichelt2, Emre F Yekebas1, Robin Wachowiak1, Alexander Quaas2, Tim Strate1, Hansjoerg Schaefer2, Guido Sauter2, Melitta Schachner3 and Jakob R Izbicki1 1Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 2Institute for Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany and 3Center for Molecular Neurobiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany The treatment strategy for mesenchymal tumors of the gastrointestinal tract is based upon typing of the tumor. Especially differential diagnosis of gastrointestinal stromal tumors (GISTs) to leiomyomas is crucial for determining radicality of surgery. L1 cell adhesion molecule (CD171) plays an essential role in tumor progression. The aim of this study was to determine expression of L1 in GISTs, smooth muscle tumors, desmoid-type fibromatosis and peripheral nerve sheath tumors (PNSTs). We retrospectively analyzed a total of 129 surgically resected primary tumors or metastases of 72 GISTs, 29 smooth muscle tumors, seven PNSTs and 21 desmoid-type fibromatosis by immunohistochemistry for c-kit, CD34, smooth muscle actin, desmin, vimentin, S-100 and L1 expression. L1 expression was detected in 53 (74%) of 72 GISTs but in none of 29 smooth muscle tumors or 21 desmoid-type fibromatosis (Po0.01 by Fisher’s test). In all, four (57%) of seven peripheral nerve sheath tumors were L1-positive. Survival analysis of 55 surgically completely resected GISTs presenting without metastasis at initial diagnosis revealed no tumor-specific death among L1-negative patients (P ¼ 0.13 by log-rank test; median follow-up time 41 months) and one recurrence was observed (P ¼ 0.12). Interestingly high levels of L1 were seen in tumor vascular endothelial cells of smooth muscle tumors and PNSTs, but not in GISTs. Our data show that L1 is highly expressed in GISTs but not in smooth muscle tumors and desmoid-type fibromatosis being important differential diagnoses. The trend towards a reduced survival of L1-positive patients in this study has to be further evaluated in future trials with higher patient numbers. Modern Pathology (2006) 19, 399–406. doi:10.1038/modpathol.3800547; published online 6 January 2006 Keywords: gastrointestinal stromal tumors; tumor markers; L1 cell adhesion molecule Gastrointestinal stromal tumors (GISTs) are a hetero- sis is important since GISTs even with low mitotic geneous group of tumors originating from the rate have a higher risk of malignant behavior and interstitial cells of Cajal that are located in the therefore require more aggressive surgery in contrast nerve plexus of the muscularis in the gut wall.1 On to, for example, leiomyomas that need to be primary manifestation the outcome of GISTs is enucleated only.6,7 Several classifications of GISTs hardly predictable and patients have a bad prog- exist, one of them is the ‘consensus approach of nosis once relapse or metastasis is discovered.2,3 The 2002’ that considers primary tumor size and mitotic remarkable antitumor activity of the protein kinase rate.1 The outcome clearly depends on these two inhibitor Imatinib (Glivecs) in GISTs requires parameters.8 Tyrosine kinase c-kit (CD117) and accurate diagnosis of this neoplasia vs other soft PDGFR play important roles for diagnosis and tissue tumors.4 Most GISTs occur in the stomach and therapy of GISTs.1–4 Another immunopathological small intestine, but rarely they also present in the marker is CD34 that is expressed in 60–70% of esophagus and large intestine.5 Differential diagno- cases.1–9 A definitive discrimination between benign and malignant GISTs, however, has not been achieved. Correspondence: Dr JT Kaifi, MD, Department of General, Visceral Cell adhesion molecule L1 (CD171), a 200– and Thoracic Surgery, University Medical Center Hamburg- 220 kDa type I glycoprotein of the immunoglobulin Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. E-mail: [email protected] superfamily, plays a role in development of the Received 16 September 2005; revised 10 November 2005; nervous system by regulating cell interactions, accepted 1 December 2005; published online 6 January 2006 including neuronal migration.10,11 It also mediates L1 expression in GISTs JT Kaifi et al 400 neuron–neuron adhesion and neurite outgrowth on Immunohistochemical Staining of L1 and Evaluation Schwann cells.11–13 L1 undergoes homophilic bind- of Expression ing, but also heterophilic interactions, for example with integrins, have been described.14,15 L1 was Immunohistochemical staining for L1 was per- detected on a variety of tumor cells of neuronal, formed on 5 mm thick sections placed on precoated mesothelial and epithelial origin, such as of neuro- slides with 3-triethoxysilylpropylamin (Merck, blastomas, melanomas, lymphomas, small cell lung, Darmstadt, Germany) of formalin-fixed tissues. After colon and breast carcinomas.16–22 After cleavage by a deparaffinization with Rotihistole (Merck) and metalloproteinase (ADAM10) from the tumor cell rehydration in ethanol and TBS (0.05 M; pH 7.6) surface L1 can be detected in serum of cancer containing 0.1% Tween 20 (Sigma, Deisenhofen, patients.10,23–26 Its presence in tumor and serum Germany), tissue sections were pretreated for 30 min has a prognostic significance in ovarian, uterine and in 1% ammonium chloride (NH4Cl) in TBS, for 15 min in 0.05 M glycine/TBS and afterwards boiled renal cell carcinomas and is associated with meta- s stasis of melanomas.22,27,28 with ChemMate Target Retrieval Solution (Dako) in The aim of our study was to evaluate whether L1 a microwave oven according to the manufacturer’s could serve as a potential diagnostical marker and instructions. Staining was performed with the prognostic factor of GISTs compared to smooth muscle avidin–biotin–peroxidase method (HRP-AEC Sys- tumors, desmoid-type fibromatosis and PNSTs. tem, Cell and Tissue Staining Kit; R&D Systems, Minneapolis, MN, USA). The primary antibody, a murine anti-human L1 monoclonal antibody (IgG1; Materials and methods Clone UJ127) (NeoMarkers, Fremont, CA, USA) binding to the extracellular domain of this molecule, Patients and Samples was diluted at 1:50 in Antibody Diluent (Dako) and slides were incubated overnight in a humidified This study was approved by the Ethics Committee of 1 the Chamber of Physicians in Hamburg, Germany. chamber at 4 C. For each sample one slide, a control Written informed consent was obtained from all section, was incubated with irrelevant murine patients for use of the resected samples. For this monoclonal IgG1 (MOPC21; Sigma) as a negative study, 72 patients with GIST, 29 with smooth muscle control to determine unspecific binding. All wash- tumors, seven with PNSTs and 21 with desmoid- ing steps were done with TBS containing 0.1% type fibromatosis that were surgically treated Tween 20. Counterstaining was performed with between 1985 and 2004 were chosen retrospectively. Mayer’s Haematoxylin solution (Merck) for 7 min. Finally, slides were cover-slipped with aqueous In 65 patients primary GISTs were examined, among s these, additional four liver and two lymph node mounting medium (Aquatex ; Merck). Peripheral metastases occurred. In seven patients only liver nerves being present in nearly all sections served as metastases were available. 18 leiomyomas and 11 internal positive controls. Additionally, peripheral leiomyosarcoma (three primary tumors, five liver nerve sections were stained separately. Immuno- and two peritoneal metastases), seven PNSTs (five histochemical analysis and scoring was performed by malignant (two primary tumors and three metastases three independent investigators (JTK, AS and UR). from lung, liver and pancreas) and two benign) and 21 desmoid-type fibromatosis (seven abdominal and Survival Data 14 extraabdominal) were also analyzed. Tumor samples from patients with mesenchymal tumors Clinical follow-up data were obtained by reviewing from the gastrointestinal tract that were possibly the hospital records, direct communication with the misdiagnosed at times when diagnostic criterias attending physicians and from the Cancer Registry for GIST were not established, were recently re- of Hamburg. Tumor-specific survival was calculated evaluated and re-classified retrospectively. Besides, from the date of surgical excision of the primary histological criterias, the following antibodies were tumor to the date of death or last follow-up. Patients used for immunohistological (re-) classification of who died from causes other than GIST were all tumors: CD117 (c-kit; rabbit polyclonal) (Dako, censored at the time of death. Patients whose death Glostrup, Denmark), CD34 (mouse IgG1) (Novocastra was clearly documented as attributable to GIST Laboratories Ltd, Newcastle, United Kingdom), considered to have died of that disease; other desmin (clone DE-R-11) (Dako), muscle actin (mouse deaths were not considered to have been caused by IgG1; clone HHF35) (Enzo Diagnostics Inc., NY, GIST. Recurrence-free survival was calculated from USA), and S-100 protein (polyclonal) (Dako). The the date of surgical excision to the date of recur- proliferative index was determined with Ki-67 rence. Peritoneal carcinosis was found in two cases (MIB1; IgG1) (Dako) and was categorized as mitotic and distant
Load more

Recommended publications
  • Clinical Significance and Biological Role of L1 Cell Adhesion Molecule In
    www.nature.com/bjc ARTICLE Molecular Diagnostics Clinical significance and biological role of L1 cell adhesion molecule in gastric cancer Takashi Ichikawa1, Yoshinaga Okugawa 1, Yuji Toiyama1, Koji Tanaka1, Chengzeng Yin1, Takahito Kitajima1, Satoru Kondo1, Tadanobu Shimura1, Masaki Ohi1, Toshimitsu Araki1 and Masato Kusunoki1 BACKGROUND: L1 cell adhesion molecule (L1CAM) is highly expressed in malignant tumours and might play a pivotal role in tumour progression. METHODS: We analysed by immunohistochemistry L1CAM protein expression in formalin-fixed, paraffin-embedded specimens from 309 GC patients. We performed propensity score matching (PSM) analysis to clarify the prognostic impact of L1CAM in GC patients. We evaluated L1CAM gene expression in fresh frozen specimens from another group of 131 GC patients to establish its clinical relevance. The effects of changes in L1CAM were investigated in vitro and in vivo. RESULTS: L1CAM was mainly expressed in tumour cells of GC tissues. Elevated L1CAM expression was an independent prognostic factor for overall and disease-free survival, and an independent risk factor for distant metastasis in GC patients. PSM analysis showed that high L1CAM expression was significantly associated with poor prognosis. L1CAM gene expression using fresh frozen specimens successfully validated all of these findings in an independent cohort. Inhibition of L1CAM suppressed cell proliferation, cycle progress, invasion, migration and anoikis resistance in GC cells. Furthermore, L1CAM inhibition suppressed the growth of peritoneal
    [Show full text]
  • Human N-Cadherin / CD325 / CDH2 Protein (His & Fc Tag)
    Human N-Cadherin / CD325 / CDH2 Protein (His & Fc Tag) Catalog Number: 11039-H03H General Information SDS-PAGE: Gene Name Synonym: CD325; CDHN; CDw325; NCAD Protein Construction: A DNA sequence encoding the human CDH2 (NP_001783.2) (Met 1-Ala 724) was fused with the C-terminal polyhistidine-tagged Fc region of human IgG1 at the C-terminus. Source: Human Expression Host: HEK293 Cells QC Testing Purity: > 70 % as determined by SDS-PAGE Endotoxin: Protein Description < 1.0 EU per μg of the protein as determined by the LAL method Cadherins are calcium dependent cell adhesion proteins, and they preferentially interact with themselves in a homophilic manner in Stability: connecting cells. Cadherin 2 (CDH2), also known as N-Cadherin (neuronal) (NCAD), is a single-pass tranmembrane protein and a cadherin containing ℃ Samples are stable for up to twelve months from date of receipt at -70 5 cadherin domains. N-Cadherin displays a ubiquitous expression pattern but with different expression levels between endocrine cell types. CDH2 Asp 160 Predicted N terminal: (NCAD) has been shown to play an essential role in normal neuronal Molecular Mass: development, which is implicated in an array of processes including neuronal differentiation and migration, and axon growth and fasciculation. The secreted recombinant human CDH2 is a disulfide-linked homodimeric In addition, N-Cadherin expression was upregulated in human HSC during protein. The reduced monomer comprises 813 amino acids and has a activation in culture, and function or expression blocking of N-Cadherin predicted molecular mass of 89.9 kDa. As a result of glycosylation, it promoted apoptosis. During apoptosis, N-Cadherin was cleaved into 20- migrates as an approximately 114 and 119 kDa band in SDS-PAGE under 100 kDa fragments.
    [Show full text]
  • L1 Induces Colon Cancer Metastasis but Not EMT and CSC Markers
    Author Manuscript Published OnlineFirst on December 1, 2010; DOI: 10.1158/1541-7786.MCR-10-0406 Author manuscripts havePublished been peer reviewed OnlineFirst and accepted on December for publication 1, 2010but have not yet been edited. L1 induces colon cancer metastasis but not EMT and CSC markers L1-mediated Colon Cancer Cell Metastasis does not Require Changes in EMT and Cancer Stem Cell Markers Nancy Gavert1, Alessia Vivanti1, John Hazin1, Thomas Brabletz2, and Avri Ben-Ze’ev1 1Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, 76100, Israel 2Department of Visceral Surgery, University of Freiburg, Hugstetter Str 55, Freiburg, 79095, Germany Running title: L1 induces colon cancer metastasis but not EMT and CSC markers Key words: L1, colon cancer, metastasis, EMT, CSC Corresponding author: Avri Ben-Ze’ev Tel: (972)-8-9342422 Fax: (972)-8-9465261 E-mail: [email protected] Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Copyright © 2010 American Association for Cancer Research Downloaded from mcr.aacrjournals.org on October 1, 2021. © 2010 American Association for Cancer Research. Author Manuscript Published OnlineFirst on December 1, 2010; DOI: 10.1158/1541-7786.MCR-10-0406 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. L1 induces colon cancer metastasis but not EMT and CSC markers Abstract Aberrant activation of WNT/β-catenin signaling is common in most sporadic and inherited colorectal cancer (CRC) cells leading to elevated β-catenin-TCF transactivation. We previously identified the neural cell adhesion molecule L1 as a target gene of β-catenin- TCF in CRC cells.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Learning from Cadherin Structures and Sequences: Affinity Determinants and Protein Architecture
    Learning from cadherin structures and sequences: affinity determinants and protein architecture Klára Fels ıvályi Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2014 © 2014 Klara Felsovalyi All rights reserved ABSTRACT Learning from cadherin structures and sequences: affinity determinants and protein architecture Klara Felsovalyi Cadherins are a family of cell-surface proteins mediating adhesion that are important in development and maintenance of tissues. The family is defined by the repeating cadherin domain (EC) in their extracellular region, but they are diverse in terms of protein size, architecture and cellular function. The best-understood subfamily is the type I classical cadherins, which are found in vertebrates and have five EC domains. Among the five different type I classical cadherins, the binding interactions are highly specific in their homo- and heterophilic binding affinities, though their sequences are very similar. As previously shown, E- and N-cadherins, two prototypic members of the subfamily, differ in their homophilic K D by about an order of magnitude, while their heterophilic affinity is intermediate. To examine the source of the binding affinity differences among type I cadherins, we used crystal structures, analytical ultracentrifugation (AUC), surface plasmon resonance (SPR), and electron paramagnetic resonance (EPR) studies. Phylogenetic analysis and binding affinity behavior show that the type I cadherins can be further divided into two subgroups, with E- and N-cadherin representing each. In addition to the affinity differences in their wild-type binding through the strand-swapped interface, a second interface also shows an affinity difference between E- and N-cadherin.
    [Show full text]
  • Cell Adhesion and Angiogenesis
    Cell adhesion and angiogenesis. J Bischoff J Clin Invest. 1997;99(3):373-376. https://doi.org/10.1172/JCI119168. Perspective Find the latest version: https://jci.me/119168/pdf Perspectives Series: Cell Adhesion in Vascular Biology Cell Adhesion and Angiogenesis Joyce Bischoff Department of Surgery, Children’s Hospital and Harvard Medical School, Children’s Hospital, Boston, Massachusetts 02115 Introduction and postcapillary venules (3). Thus, the formation of a new mi- Angiogenesis is the growth of new capillary blood vessels from crovessel requires a number of interactions that must be coor- preexisting capillaries and postcapillary venules. This process dinated in a spatially and temporally specified manner. These is critical for normal growth and development and in protec- adhesion events are likely mediated by endothelial cell adhe- tive responses such as wound healing and inflammation. In sion molecules and ECM molecules that provide instructions healthy adults, angiogenesis does not normally occur except in to the endothelial cells as they migrate into the perivascular certain phases of the female reproductive cycle. However, ab- space and assemble into new vessels with surrounding peri- errant angiogenesis can occur in a variety of pathologic set- cytes. tings. These include the neovascularization of solid tumors, the Cell adhesion and endothelial cell growth growth of vessels into the retina in diabetic retinopathy, and the unwanted vessel growth in chronic inflammatory diseases. Adhesion of endothelial cells to ECM and attainment of an The hypothesis that angiogenic diseases, in particular tumor appropriate cellular shape has been known for many years to growth and metastases, may be alleviated by inhibiting the an- be crucial for endothelial cell growth, differentiation, and sur- giogenic responses (1) has prompted many to investigate the vival.
    [Show full text]
  • L1 Cell Adhesion Molecule in Cancer, a Systematic Review on Domain-Specific Functions
    International Journal of Molecular Sciences Review L1 Cell Adhesion Molecule in Cancer, a Systematic Review on Domain-Specific Functions Miriam van der Maten 1,2, Casper Reijnen 1,3, Johanna M.A. Pijnenborg 1,* and Mirjam M. Zegers 2,* 1 Department of Obstetrics and Gynaecology, Radboud university medical center, 6525 GA Nijmegen, The Netherlands 2 Department of Cell Biology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, 6525 GA Nijmegen, The Netherlands 3 Department of Obstetrics and Gynaecology, Canisius-Wilhelmina Hospital, 6532 SZ Nijmegen, The Netherlands * Correspondence: [email protected] (J.M.A.P); [email protected] (M.M.Z.) Received: 24 June 2019; Accepted: 23 August 2019; Published: 26 August 2019 Abstract: L1 cell adhesion molecule (L1CAM) is a glycoprotein involved in cancer development and is associated with metastases and poor prognosis. Cellular processing of L1CAM results in expression of either full-length or cleaved forms of the protein. The different forms of L1CAM may localize at the plasma membrane as a transmembrane protein, or in the intra- or extracellular environment as cleaved or exosomal forms. Here, we systematically analyze available literature that directly relates to L1CAM domains and associated signaling pathways in cancer. Specifically, we chart its domain-specific functions in relation to cancer progression, and outline pre-clinical assays used to assess L1CAM. It is found that full-length L1CAM has both intracellular and extracellular targets, including interactions with integrins, and linkage with ezrin. Cellular processing leading to proteolytic cleavage and/or exosome formation results in extracellular soluble forms of L1CAM that may act through similar mechanisms as compared to full-length L1CAM, such as integrin-dependent signals, but also through distinct mechanisms.
    [Show full text]
  • CDH1 Gene Cadherin 1
    CDH1 gene cadherin 1 Normal Function The CDH1 gene provides instructions for making a protein called epithelial cadherin or E-cadherin. This protein is found within the membrane that surrounds epithelial cells, which are the cells that line the surfaces and cavities of the body, such as the inside of the eyelids and mouth. E-cadherin belongs to a family of proteins called cadherins whose function is to help neighboring cells stick to one another (cell adhesion) to form organized tissues. Another protein called p120-catenin, produced from the CTNND1 gene, helps keep E-cadherin in its proper place in the cell membrane, preventing it from being taken into the cell through a process called endocytosis and broken down prematurely. E-cadherin is one of the best-understood cadherin proteins. In addition to its role in cell adhesion, E-cadherin is involved in transmitting chemical signals within cells, controlling cell maturation and movement, and regulating the activity of certain genes. Interactions between the E-cadherin and p120-catenin proteins, in particular, are thought to be important for normal development of the head and face (craniofacial development), including the eyelids and teeth. E-cadherin also acts as a tumor suppressor protein, which means it prevents cells from growing and dividing too rapidly or in an uncontrolled way. Health Conditions Related to Genetic Changes Breast cancer Inherited mutations in the CDH1 gene increase a woman's risk of developing a form of breast cancer that begins in the milk-producing glands (lobular breast cancer). In many cases, this increased risk occurs as part of an inherited cancer disorder called hereditary diffuse gastric cancer (HDGC) (described below).
    [Show full text]
  • A Novel Recombinant Anti-CD22 Immunokinase Delivers
    Published OnlineFirst January 29, 2016; DOI: 10.1158/1535-7163.MCT-15-0685 Large Molecule Therapeutics Molecular Cancer Therapeutics A Novel Recombinant Anti-CD22 Immunokinase Delivers Proapoptotic Activity of Death- Associated Protein Kinase (DAPK) and Mediates Cytotoxicity in Neoplastic B Cells Nils Lilienthal1,2, Gregor Lohmann1, Giuliano Crispatzu1, Elena Vasyutina1, Stefan Zittrich3, Petra Mayer1, Carmen Diana Herling4, Mehmet Kemal Tur5, Michael Hallek4, Gabriele Pfitzer3, Stefan Barth6,7, and Marco Herling1,4 Abstract The serine/threonine death-associated protein kinases (DAPK) SGIII against the B-cell–exclusive endocytic glyco-receptor CD22 provide pro-death signals in response to (oncogenic) cellular stres- was created. Its high purity and large-scale recombinant production ses. Lost DAPK expression due to (epi)genetic silencing is found in a provided a stable, selectively binding, and efficiently internalizing broad spectrum of cancers. Within B-cell lymphomas, deficiency of construct with preserved robust catalytic activity. DK1KD-SGIII the prototypic family member DAPK1 represents a predisposing or specifically and efficiently killed CD22-positive cells of lymphoma early tumorigenic lesion and high-frequency promoter methylation lines and primary CLL samples, sparing healthy donor– or CLL marks more aggressive diseases. On the basis of protein studies and patient–derived non-B cells. The mode of cell death was predom- meta-analyzed gene expression profiling data, we show here that inantly PARP-mediated and caspase-dependent conventional apo- within the low-level context of B-lymphocytic DAPK, particularly ptosis as well as triggering of an autophagic program. The notori- CLL cells have lost DAPK1 expression. To target this potential ously high apoptotic threshold of CLL could be overcome by vulnerability, we conceptualized B-cell–specific cytotoxic reconsti- DK1KD-SGIII in vitro also in cases with poor prognostic features, tution of the DAPK1 tumor suppressor in the format of an immu- such as therapy resistance.
    [Show full text]
  • Bidirectional Crosstalk Between PD-L1 Expression and Epithelial To
    Alsuliman et al. Molecular Cancer (2015) 14:149 DOI 10.1186/s12943-015-0421-2 RESEARCH Open Access Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells Abdullah Alsuliman1, Dilek Colak2, Olfat Al-Harazi2, Hanaa Fitwi1, Asma Tulbah3, Taher Al-Tweigeri4, Monther Al-Alwan1,5 and Hazem Ghebeh1,5* Abstract Background: The T-cell inhibitory molecule PD-L1 (B7-H1, CD274) is expressed on tumor cells of a subset of breast cancer patients. However, the mechanism that regulates PD-L1 expression in this group of patients is still not well-identified. Methods: We have used loss and gain of function gene manipulation approach, multi-parametric flow cytometry, large scale gene expression dataset analysis and immunohistochemistry of breast cancer tissue sections. Results: Induction of epithelial to mesenchymal transition (EMT) in human mammary epithelial cells upregulated PD-L1 expression, which was dependent mainly on the activation of the PI3K/AKT pathway. Interestingly, gene expression signatures available from large cohort of breast tumors showed a significant correlation between EMT score and the PD-L1 mRNA level (p < 0.001). Strikingly, very strong association (p < 0.0001) was found between PD-L1 expression and claudin-low subset of breast cancer, which is known to have high EMT score. On the protein level, significant correlation was found between PD-L1 expression and standard markers of EMT (p =0.005)in67breast cancer patients. Importantly, specific downregulation of PD-L1 in claudin-low breast cancer cells showed signs of EMT reversal as manifested by CD44 and Vimentin downregulation and CD24 upregulation.
    [Show full text]
  • Characterization of the Neuron-Specific L1-CAM
    4160 Biochemistry 2008, 47, 4160–4168 Characterization of the Neuron-Specific L1-CAM Cytoplasmic Tail: Naturally Disordered in Solution It Exercises Different Binding Modes for Different Adaptor Proteins† Sergiy Tyukhtenko,‡ Lalit Deshmukh,‡ Vineet Kumar,‡ Jeffrey Lary,§ James Cole,| Vance Lemmon,⊥ and Olga Vinogradova*,‡ Department of Pharmaceutical Sciences, School of Pharmacy, Department of Molecular and Cell Biology, and Biotechnology Center, UniVersity of Connecticut, Storrs, Connecticut 06269, and The Miami Project to Cure Paralysis and Neurological Surgery, UniVersity of Miami, Miami, Florida 33136 ReceiVed December 13, 2007; ReVised Manuscript ReceiVed February 11, 2008 ABSTRACT: L1, a highly conserved transmembrane glycoprotein member of the immunoglobulin superfamily of cell adhesion molecules, mediates many developmental processes in the nervous system. Here we present the biophysical characterization and the binding properties of the least structurally defined part of this receptor: its cytoplasmic tail (CT). We have shown by analytical ultracentrifugation and dynamic light scattering experiments that it is mostly monomeric and unstructured in aqueous solution. We have defined by nuclear magnetic resonance the molecular details of L1-CT binding to two major targets: a membrane-cytoskeletal linker (MCL), ezrin, and an endocytosis mediator, AP2. Surprisingly, in addition to the two previously identified ezrin binding motifs, the juxtamembrane and the 1176YRSLE regions, we have discovered a third one, a part of which has been previously associated with binding to another MCL, ankyrin. For the L1 interaction with AP2 we have determined the precise interaction region surrounding the 1176YRSLE binding site and that this overlaps with the second ezrin binding site. In addition, we have shown that the juxtamembrane region of L1-CT has some binding affinity to AP2-µ2, although the specificity of this interaction needs further investigation.
    [Show full text]
  • Increased Expression of Cell Adhesion Molecule P-Selectin in Active Inflammatory Bowel Disease Gut: First Published As 10.1136/Gut.36.3.411 on 1 March 1995
    Gut 1995; 36: 411-418 411 Increased expression of cell adhesion molecule P-selectin in active inflammatory bowel disease Gut: first published as 10.1136/gut.36.3.411 on 1 March 1995. Downloaded from G M Schurmann, A E Bishop, P Facer, M Vecchio, J C W Lee, D S Rampton, J M Polak Abstract proposed, entailing margination from the The pathogenic changes of inflammatory centreline of blood flow towards the vascular bowel disease (IBD) depend on migration wall, rolling, tethering to the endothelia, stable of circulating leucocytes into intestinal adhesion, and finally, transendothelial migra- tissues. Although leucocyte rolling and tion.1 Each of these steps involves specific fam- tenuous adhesion are probably regulated ilies of adhesion molecules, which are by inducible selectins on vascular expressed on endothelial cells and on circulat- endothelia, little is known about the ing cells as their counterparts and ligands.2 3 expression of these molecules in Crohn's The selectin family of adhesion molecules, disease and ulcerative colitis. Using which comprises E-selectin, P-selectin, and L- immunohistochemistry on surgically selectin, predominantly mediates the first steps resected specimens, this study investi- of cellular adhesion4 5 and several studies have gated endothelial P-selectin (CD62, gran- shown upregulation of E-selectin on activated ular membrane protein-140) in frozen endothelial cells in a variety oftissues6-8 includ- sections of histologically uninvolved ing the gut in patients with IBD.9 10 Little tissues adjacent to inflammation (Crohn's investigation has been made, however, of P- disease= 10; ulcerative colitis= 10), from selectin in normal and diseased gut, although highly inflamed areas (Crohn's its DNA was cloned and sequenced in 1989.11 disease=20; ulcerative colitis=13), and P-selectin (also known as PADGEM, from normal bowel (n=20).
    [Show full text]